BioSpace News Archive

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the appointment of Jörn Drappa, MD, PhD, to its Board of Directors.

Dr. Daniel Alexander , MD joins a growing Auburn Orthopedic Specialists Practice (AOS) that is affiliated with Auburn Community Hospital.

Avantor, Inc. has appointed veteran strategy and M&A executive, Kitty Sahin, to the newly created role of EVP, Strategy and Corporate Development, effective immediately.

Adhera Therapeutics, Inc. (OTCQB: ATRX) (“Adhera” or the “Company”), a clinical stage biopharmaceutical company, today announces that the Company has entered a Heads of Terms (also known as a Letter of Intent (“LOI”)) agreement with Bio Innovation Group to acquire Paclitaxel Gallium Transferrin (“PGT”).

Paragonix Technologies , the leading hypothermic organ preservation provider, announced today its expanded enrollment in its GUARDIAN series of clinical registries aimed at investigating the impact of organ preservation.

Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced the publication of positive results from the RELIEF clinical trial in the American Journal of Rhinology & Allergy.

Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), today announced that successful production of a synthetic recombinant version of the proenzyme trypsinogen was completed via the Proenzyme Optimization Project 1 (POP1) joint research and drug discovery program.

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce its upcoming presentation of “Autopsy-Confirmed Minimally Invasive Biomarker Identifies Alzheimer’s Disease even in the Presence of Co-Morbid Pathologies” at the Alzheimer’s Association International Conference.

Cosán, a provider of technology-driven preventative care services for older adults and the physicians that support them, and Genomind, a leading precision healthcare company, have partnered to fill an existing gap in aging adult care management by providing Cosán’s network of physicians with Genomind’s integrated precision medication management platform.

According to Vision Research Reports, the global 3D printed drugs market was reached at USD 72.25 million in 2021 and it is predicted to surpass around USD 269.97 million by 2030 with a CAGR of 15.77% from 2022 to 2030.